Zusammenfassung
Immuntherapie bei malignen Erkrankungen ist definiert als ein systemtherapeutischer Ansatz, der auf die Fähigkeit des körpereigenen Immunsystems abzielt, die Entstehung von malignen Tumoren zu verhindern, bzw. bestehende Tumoren zu bekämpfen. Hierunter fallen heutzutage sehr unterschiedliche Therapieformen, wie Immuncheckpoint-Inhibitoren, BiTEs, CAR-T-Zellen und onkolytische Viren, die unterschiedliche Wirkmechanismen und Angriffspunkte haben und auch eine sehr unterschiedliche Effizienz in der Behandlung von soliden und hämatologischen Malignomen aufweisen. Zweifellos bereichern diese Ansätze das therapeutische Portfolio in der Onkologie, in der palliativen Systemtherapie, aber auch im Zusammenspiel mit operativen und ablativen lokaltherapeutischen Ansätzen.
Abstract
Immunotherapy for malignant diseases is defined as a systematic therapeutic approach that aims to target the individual’s immune system to prevent the development of malignancies or to combat existing tumors. Nowadays, this includes various therapeutic approaches, such as immune checkpoint inhibitors, BiTEs (bispecific T‑cell engagers), CAR T‑cells (CAR: chimeric antigen receptors) and oncolytic viruses, which have not only different mechanisms of action and points of attack, but also have very different efficiencies in the treatment of solid and hematological malignancies. These approaches undoubtedly enrich the therapeutic portfolio in oncology—in palliative systematic therapy and also in the interaction with operative and ablative local therapeutic approaches.
Literatur
Verwendete Literatur
Papaioannou NE, Beniata OV, Vitsos P, Tsitsilonis O, Samara P (2016) Harnessing the immune system to improve cancer therapy. Ann Transl Med 4(14):261
Coley WB (1893) The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci 105:487–511
McCarthy EF (2006) The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J 26:154–158
Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G (2014) Classification of current anticancer immunotherapies. Oncotarget 5(24):12472–12508
Bracci L, Schiavoni G, Sistigu A, Belardelli F (2014) Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ 21(1):15–25. https://doi.org/10.1038/cdd.2013.67
Nardin A, Wong WC, Tow C, Molina TJ, Tissier F, Audebourg A, Garcette M, Caignard A, Avril MF, Abastado JP, Prévost-Blondel A (2011) Dacarbazine promotes stromal remodeling and lymphocyte infiltration in cutaneous melanoma lesions. J Invest Dermatol 131(9):1896–1905
Baeuerle PA, Reinhardt C (2009) Bispecific T‑cell engaging antibodies for cancer therapy. Cancer Res 69(12):4941–4944
Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, Diedrich H, Topp MS, Brüggemann M, Horst HA, Havelange V, Stieglmaier J, Wessels H, Haddad V, Benjamin JE, Zugmaier G, Nagorsen D, Bargou RC (2018) Blinatumomab for minimal residual disease in adults with B‑cell precursor acute lymphoblastic leukemia. Blood 131(14):1522–1531
Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS (2017) Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376(9):836–847
Gong MC, Latouche JB, Krause A, Heston WD, Bander NH, Sadelain M (1999) Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1(2):123–127
Kalos M, June CH (2013) Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 39(1):49–60
Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö, Salles G, Maziarz RT, JULIET Investigators. (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B‑cell lymphoma. N Engl J Med 380(1):45–56
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY (2017) Axicabtagene ciloleucel CAR T‑cell therapy in refractory large B‑cell lymphoma. N Engl J Med 377(26):2531–2544
American Society of Clinical Oncology (ASCO) (2020) Webpräsenz. https://www.asco.org. Zugegriffen: 04.2020
Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA (2018) Tisagenlecleucel in children and young adults with B‑cell lymphoblastic leukemia. N Engl J Med 378(5):439–448
Kaufman HL, Kohlhapp FJ, Zloza A (2015) Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 14(9):642–662 (Erratum in: Nat Rev Drug Discov. 2016 Aug 30;15(9):660)
de Gruijl TD, Janssen AB, van Beusechem VW (2015) Arming oncolytic viruses to leverage antitumor immunity. Expert Opin Biol Ther 15(7):959–971
Achard C, Surendran A, Wedge ME, Ungerechts G, Bell J, Ilkow CS (2018) Lighting a fire in the tumor microenvironment using oncolytic immunotherapy. EBioMedicine 31:17–24
Kohlhapp FJ, Kaufman HL (2016) Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy. Clin Cancer Res 22(5):1048–1054
Postow MA, Callahan MK, Wolchok JD (2015) Immune checkpoint blockade in cancer therapy. J Clin Oncol 33(17):1974–1982
Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S (2012) Immunotherapy of cancer in 2012. CA Cancer J Clin 62(5):309–335
Davis ID (2000) An overview of cancer immunotherapy. Immunol Cell Biol 78(3):179–195
Weiterführende Literatur
CleanPNG (2020) Water circle. https://www.cleanpng.com/png-antibody-dependent-cell-mediated-cytotoxicity-cell-1794345/preview.html;. Zugegriffen: 04.2020
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
G. Schilling und D. Arnold geben an, dass kein Interessenkonflikt besteht.
Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Rights and permissions
About this article
Cite this article
Schilling, G., Arnold, D. Grundlagen der Immuntherapie. Radiologe 60, 682–686 (2020). https://doi.org/10.1007/s00117-020-00720-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00117-020-00720-3